JP2020531532A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020531532A5 JP2020531532A5 JP2020511375A JP2020511375A JP2020531532A5 JP 2020531532 A5 JP2020531532 A5 JP 2020531532A5 JP 2020511375 A JP2020511375 A JP 2020511375A JP 2020511375 A JP2020511375 A JP 2020511375A JP 2020531532 A5 JP2020531532 A5 JP 2020531532A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- seq
- amino acid
- acid sequence
- hcvr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023169177A JP2023182691A (ja) | 2017-08-22 | 2023-09-29 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762548632P | 2017-08-22 | 2017-08-22 | |
| US62/548,632 | 2017-08-22 | ||
| PCT/US2018/047286 WO2019040471A1 (en) | 2017-08-22 | 2018-08-21 | METHODS OF TREATING UREA CYCLE DISORDERS BY INTERFERING WITH GLUCAGON RECEPTOR SIGNALING |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023169177A Division JP2023182691A (ja) | 2017-08-22 | 2023-09-29 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020531532A JP2020531532A (ja) | 2020-11-05 |
| JP2020531532A5 true JP2020531532A5 (https=) | 2021-09-30 |
| JP7781519B2 JP7781519B2 (ja) | 2025-12-08 |
Family
ID=63638351
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020511375A Active JP7781519B2 (ja) | 2017-08-22 | 2018-08-21 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
| JP2023169177A Pending JP2023182691A (ja) | 2017-08-22 | 2023-09-29 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023169177A Pending JP2023182691A (ja) | 2017-08-22 | 2023-09-29 | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12139546B2 (https=) |
| EP (1) | EP3672620A1 (https=) |
| JP (2) | JP7781519B2 (https=) |
| CA (1) | CA3071387A1 (https=) |
| MX (2) | MX2020002057A (https=) |
| WO (1) | WO2019040471A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020210642A1 (en) * | 2019-04-10 | 2020-10-15 | Camp4 Therapeutics Corporation | Methods and compositions for treating urea cycle disorders |
| CA3205005A1 (en) * | 2020-12-16 | 2022-06-23 | Rush University Medical Center | Administration of glycerol tribenzoate and glycerol phenylbutyrate for treatment of neurodegenerative and urea cycle disorders |
| MX2024007790A (es) * | 2021-12-22 | 2024-09-06 | Camp4 Therapeutics Corp | Modulación de la transcripción génica utilizando oligonucleótidos antisentido dirigidos a arn reguladores. |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5836308B2 (ja) | 1977-02-10 | 1983-08-08 | 大塚製薬株式会社 | 抗体の製造方法 |
| US4206199A (en) | 1977-07-22 | 1980-06-03 | Takeda Chemical Industries, Ltd. | Novel glucagon fragment and its derivatives |
| JPS56163456A (en) | 1980-05-21 | 1981-12-16 | Otsuka Pharmaceut Co Ltd | Preparation of antigen |
| US4423034A (en) | 1980-10-16 | 1983-12-27 | Toyo Jozo Kabushiki Kaisha | Process for the preparation of antibodies |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0658200B1 (en) | 1992-08-28 | 2004-12-22 | Novo Nordisk A/S | Glucagon receptors |
| JP2729159B2 (ja) | 1994-10-31 | 1998-03-18 | 日清製粉株式会社 | ヒトグリセンチンのモノクローナル抗体、この抗体を産生するハイブリドーマおよびそれを用いるヒトグリセンチンの定量法 |
| US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
| CA2547785A1 (en) | 2003-12-19 | 2005-07-21 | Merck & Co., Inc. | Cyclic guanidines, compositions containing such compounds and methods of use |
| DE602005006806D1 (de) | 2004-06-04 | 2008-06-26 | Merck & Co Inc | Pyrazolderivate, zusammensetzungen, die solche verbindungen enthalten, und anwendungsverfahren |
| DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
| AU2005272043B2 (en) | 2004-07-07 | 2010-07-29 | Merck Sharp & Dohme Corp. | Pyrazole amide derivatives, compositions containing such compounds and methods of use |
| US7625938B2 (en) | 2004-07-22 | 2009-12-01 | Merck & Co., Inc. | Substituted pyrazoles, compositions containing such compounds and methods of use |
| SI1856090T1 (sl) | 2005-02-11 | 2010-02-26 | Lilly Co Eli | Substituirani derivati tiofena kot antagonisti glukagonskega receptorja, priprava in terapevtske uporabe |
| US8318760B2 (en) | 2005-03-21 | 2012-11-27 | Merck Sharp & Dohme Corp. | Substituted aryl and heteroaryl derivatives, compositions containing such compounds and methods of use |
| US7803951B2 (en) | 2005-03-30 | 2010-09-28 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| AR056574A1 (es) | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
| CA2649751A1 (en) | 2006-04-20 | 2007-11-01 | Amgen Inc. | Glp-1 compound/glucagon antibody compositions |
| CL2007002668A1 (es) | 2006-09-20 | 2008-05-09 | Amgen Inc | Proteina de union a antigeno que se une al receptor de glucagon humano; acido nucleico que la codifica; metodo de produccion; composicion farmaceutica que la comprende; y su uso para tratar o prevenir la diabetes tipo 2. |
| TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| KR20190126460A (ko) | 2007-02-09 | 2019-11-11 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
| CL2009000586A1 (es) | 2008-03-27 | 2010-06-04 | Lilly Co Eli | Fragmento fab o anticuerpo monoclonal humanizado que lo comprende que se une a receptor de glucagon humano/glucr, de rata, de raton, y mono cinomolgus; vector que comprende polinuccleotido codificante; celula huesped que lo comprende; composicion farmaceutica; uso para tratar diabetes tipo 1 o 2, o para la perdida de peso |
| EP2291358B1 (en) | 2008-05-16 | 2018-03-28 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonists, compositions, and methods for their use |
| EP2346830B1 (en) | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| WO2010071750A1 (en) | 2008-12-19 | 2010-06-24 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
| US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8324384B2 (en) | 2009-02-12 | 2012-12-04 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8809579B2 (en) | 2009-02-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| US8318667B2 (en) | 2009-02-25 | 2012-11-27 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
| JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | ３−（４−置換アルキル−フェニル）−２−フランカルボン酸誘導体およびその薬学的に許容される塩 |
| FR2959129B1 (fr) * | 2010-04-21 | 2013-02-01 | Lucane Pharma | Particules comprenant du 4-phenylbutyrate de sodium, procede de preparation et utilisations |
| JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
| DK2760479T3 (en) | 2011-09-30 | 2017-07-17 | Horizon Therapeutics Llc | Nitrogen-removing drug for use in a method of treating a nitrogen retention disorder |
| US9453073B2 (en) | 2011-12-02 | 2016-09-27 | Eli Lilly And Company | Anti-glucagon antibodies and uses thereof |
| KR20170062466A (ko) | 2014-09-16 | 2017-06-07 | 리제너론 파마슈티칼스 인코포레이티드 | 항-글루카곤 항체 및 그것의 사용 |
-
2018
- 2018-08-21 CA CA3071387A patent/CA3071387A1/en active Pending
- 2018-08-21 JP JP2020511375A patent/JP7781519B2/ja active Active
- 2018-08-21 WO PCT/US2018/047286 patent/WO2019040471A1/en not_active Ceased
- 2018-08-21 MX MX2020002057A patent/MX2020002057A/es unknown
- 2018-08-21 EP EP18772997.5A patent/EP3672620A1/en active Pending
- 2018-08-21 US US16/640,907 patent/US12139546B2/en active Active
-
2020
- 2020-02-21 MX MX2024011106A patent/MX2024011106A/es unknown
-
2023
- 2023-09-29 JP JP2023169177A patent/JP2023182691A/ja active Pending
-
2024
- 2024-10-03 US US18/906,101 patent/US20250101119A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Auron et al. | Hyperammonemia in review: pathophysiology, diagnosis, and treatment | |
| JP2023182691A5 (https=) | ||
| Collins et al. | Oral sodium phenylbutyrate therapy in homozygous beta thalassemia: a clinical trial | |
| US6011000A (en) | Compositions for the treatment of blood disorders | |
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2020531532A5 (https=) | ||
| JP7398958B2 (ja) | 安定的抗ｏｓｍｒ抗体製剤 | |
| WO2009070378A1 (en) | Compositions and methods for inhibiting the activation of dsrna-dependent protein kinase and tumor growth inhibition | |
| US9107894B2 (en) | Formulation to improve gastrointestinal function | |
| JP2022121658A (ja) | アミロイドーシスを処置するための組成物 | |
| CN118105485B (zh) | 一种稳定的抗人IL-4Rα单克隆抗体制剂 | |
| EP4530297A1 (en) | Anti-asgr1 monoclonal antibody and use thereof | |
| JP7781519B2 (ja) | グルカゴン受容体シグナル伝達に干渉することによって尿素サイクル異常症を治療する方法 | |
| AU2010274030A1 (en) | Treating patients with intravenous ibuprofen | |
| WO2017177160A1 (en) | Formulation for use in a method of treatment of pain | |
| JPWO2023019171A5 (https=) | ||
| Savy | Enteral glutamine supplementation: clinical review and practical guidelines | |
| Mäkelä et al. | Dosage of Salicylates for Children with Juvenile Rheumatoid Arthritis: A Preliminary Report | |
| WO2019236658A2 (en) | Pic1 peptide compositions and methods of use thereof for treatment of drug-induced immune hemolytic anemia | |
| JPWO2023086817A5 (https=) | ||
| Saborio et al. | Chronic renal failure: An overview from a pediatric perspective | |
| US7910624B1 (en) | Compositions for the treatment of blood disorders | |
| EP3784243B1 (en) | Methotrexate for use as a medicament | |
| US20250221954A1 (en) | Methods to treat, prevent, or reduce hyperammonemia | |
| JP2024516615A (ja) | 高アンモニア血症の処置 |